Skip to content
2000
image of Breast Cancer Drug Resistance: Precision Targeting of ER and HER2 Signalling Networks

Abstract

Breast cancer (BC) continues to be a significant challenge in oncology, primarily due to the emergence of drug resistance, which severely limits treatment efficacy and adversely affects patient outcomes. This review aims to elucidate the mechanisms underlying drug resistance in BC, focusing on the roles of the estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2) signaling pathways. It identifies advanced therapeutic strategies that effectively target and overcome resistance by analyzing these pathways. This review integrates a comprehensive selection of clinical data and cell lines with known resistance profiles, encompassing both clinical and laboratory settings. It employs cutting-edge techniques such as high-throughput sequencing, proteomics, and advanced imaging. Key measurements include receptor expression levels, pathway activation states, and drug response data, analyzed using bioinformatics tools for genetic and proteomic insights and statistical models to determine the clinical significance of the findings. The review identifies specific mutations and alterations in the ER and HER2 pathways that contribute to drug resistance. Notably, it highlights novel biomarkers and resistance mechanisms, including the upregulation of alternative signaling cascades and mutations in downstream effectors. It also emphasizes promising targeted therapeutic strategies, such as combination therapies and next-generation inhibitors, which have demonstrated encouraging results in preclinical models. In conclusion, this review provides critical insights into the intricate mechanisms of drug resistance in BC, underscoring the pivotal roles of the ER and HER2 signaling pathways. It identifies unique resistance mechanisms and potential therapeutic targets, paving the way for the development of advanced strategies to improve treatment outcomes.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cpd/10.2174/0113816128406867251204172244
2026-02-26
2026-03-08

  • From This Site

    /content/journals/cpd/10.2174/0113816128406867251204172244
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Sung H. Ferlay J. Siegel R.L. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2021 71 3 209 249 10.3322/caac.21660 33538338
    [Google Scholar]
  2. Daniele A. Divella R. Pilato B. Can harmful lifestyle, obesity and weight changes increase the risk of breast cancer in BRCA 1 and BRCA 2 mutation carriers? A Mini review. Hered. Cancer Clin. Pract. 2021 19 1 45 10.1186/s13053‑021‑00199‑6 34706754
    [Google Scholar]
  3. Le-Petross H.T. Cristofanilli M. Carkaci S. MRI features of inflammatory breast cancer. AJR Am. J. Roentgenol. 2011 197 4 W769-76 10.2214/AJR.10.6157 21940550
    [Google Scholar]
  4. Autier P. Boniol M. Mammography screening: A major issue in medicine. Eur. J. Cancer 2018 90 34 62 10.1016/j.ejca.2017.11.002 29272783
    [Google Scholar]
  5. Obeagu E.I. Obeagu G.U. BRCA Mastery: Redefining breast cancer care through cutting-edge diagnosis and management. Elite J Med 2024 55 66
    [Google Scholar]
  6. Rahman M. Mohammed S. Breast cancer metastasis and the lymphatic system. Oncol. Lett. 2015 10 3 1233 1239 10.3892/ol.2015.3486 26622656
    [Google Scholar]
  7. Cong B. Cao X. Jiang W. Ye L. Molecular and cellular machinery of lymphatic metastasis in breast cancer. OncoTargets Ther. 2025 18 199 209 10.2147/OTT.S503272 39926374
    [Google Scholar]
  8. Szymiczek A. Lone A. Akbari M.R. Molecular intrinsic versus clinical subtyping in breast cancer: A comprehensive review. Clin. Genet. 2021 99 5 613 637 10.1111/cge.13900 33340095
    [Google Scholar]
  9. Harbeck N. Penault-Llorca F. Cortes J. Breast cancer. Nat. Rev. Dis. Primers 2019 5 1 66 10.1038/s41572‑019‑0111‑2 31548545
    [Google Scholar]
  10. Smolarz B. Nowak A.Z. Romanowicz H. Breast cancer epidemiology, classification, pathogenesis and treatment. Cancers (Basel) 2022 14 10 2569 10.3390/cancers14102569 35626173
    [Google Scholar]
  11. Hsu J.L. Hung M.C. The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer. Cancer Metastasis Rev. 2016 35 4 575 588 10.1007/s10555‑016‑9649‑6 27913999
    [Google Scholar]
  12. Kamdje A.H.N. Seke Etet P.F. Vecchio L. New targeted therapies for breast cancer: A focus on tumor microenvironmental signals and chemoresistant breast cancers. World J. Clin. Cases 2014 2 12 769 786 10.12998/wjcc.v2.i12.769 25516852
    [Google Scholar]
  13. Uribe M.L. Marrocco I. Yarden Y. EGFR in cancer: Signalling mechanisms, drugs, and acquired resistance. Cancers (Basel) 2021 13 11 2748 10.3390/cancers13112748 34206026
    [Google Scholar]
  14. Choi Y. Kim H. Pollack S. ERβ isoforms have differential clinical significance in breast cancer subtypes and subgroups. Curr. Issues Mol. Biol. 2022 44 4 1564 1586 10.3390/cimb44040107 35723365
    [Google Scholar]
  15. Dhiwar P.S. Purawarga Matada G.S. Pal R. An assessment of EGFR and HER2 inhibitors with structure activity relationship of fused pyrimidine derivatives for breast cancer: a brief review. J. Biomol. Struct. Dyn. 2024 42 3 1564 1581 10.1080/07391102.2023.2204351 37158086
    [Google Scholar]
  16. Wee P. Wang Z. Epidermal growth factor receptor cell proliferation signaling pathways. Cancers (Basel) 2017 9 5 52 10.3390/cancers9050052 28513565
    [Google Scholar]
  17. Mustafa M. Abbas K. Alam M. Molecular pathways and therapeutic targets linked to triple-negative breast cancer (TNBC). Mol. Cell. Biochem. 2024 479 4 895 913 10.1007/s11010‑023‑04772‑6 37247161
    [Google Scholar]
  18. Giovannelli P. Di Donato M. Galasso G. Di Zazzo E. Bilancio A. Migliaccio A. The androgen receptor in breast cancer. Front. Endocrinol. (Lausanne) 2018 9 492 10.3389/fendo.2018.00492 30210453
    [Google Scholar]
  19. Wu M. Zhang P. EGFR-mediated autophagy in tumourigenesis and therapeutic resistance. Cancer Lett. 2020 469 207 216 10.1016/j.canlet.2019.10.030 31639425
    [Google Scholar]
  20. Chow C.Y.C. Lie E.F. Wu C.H. Chow L.W.C. Clinical implication of genetic composition and molecular mechanism on treatment strategies of HER2-positive breast cancers. Front. Oncol. 2022 12 964824 10.3389/fonc.2022.964824 36387174
    [Google Scholar]
  21. Li X. Zhao L. Chen C. Nie J. Jiao B. Can EGFR be a therapeutic target in breast cancer? Biochim. Biophys. Acta Rev. Cancer 2022 1877 5 188789 10.1016/j.bbcan.2022.188789 36064121
    [Google Scholar]
  22. Zakaria Z. Zulkifle M.F. Wan Hasan W.A.N. Epidermal growth factor receptor (EGFR) gene alteration and protein overexpression in Malaysian triple-negative breast cancer (TNBC) cohort. OncoTargets Ther. 2019 12 7749 7756 10.2147/OTT.S214611 31571924
    [Google Scholar]
  23. Salgado R. Denkert C. Demaria S. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann. Oncol. 2015 26 2 259 271 10.1093/annonc/mdu450 25214542
    [Google Scholar]
  24. Mendelsohn J. Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000 19 56 6550 6565 10.1038/sj.onc.1204082 11426640
    [Google Scholar]
  25. Karami Fath M. Azargoonjahromi A. Kiani A. The role of epigenetic modifications in drug resistance and treatment of breast cancer. Cell. Mol. Biol. Lett. 2022 27 1 52 10.1186/s11658‑022‑00344‑6 35764927
    [Google Scholar]
  26. Masuda H. Zhang D. Bartholomeusz C. Doihara H. Hortobagyi G.N. Ueno N.T. Role of epidermal growth factor receptor in breast cancer. Breast Cancer Res. Treat. 2012 136 2 331 345 10.1007/s10549‑012‑2289‑9 23073759
    [Google Scholar]
  27. Du B. Shim J. Targeting epithelial-mesenchymal transition (EMT) to overcome drug resistance in cancer. Molecules 2016 21 7 965 10.3390/molecules21070965 27455225
    [Google Scholar]
  28. You K.S. Yi Y.W. Cho J. Park J.S. Seong Y.S. Potentiating therapeutic effects of epidermal growth factor receptor inhibition in triple-negative breast cancer. Pharmaceuticals (Basel) 2021 14 6 589 10.3390/ph14060589 34207383
    [Google Scholar]
  29. Zhou Z. Kennell C. Jafari M. Sequential delivery of erlotinib and doxorubicin for enhanced triple negative Breast cancer treatment using polymeric nanoparticle. Int. J. Pharm. 2017 530 1-2 300 307 10.1016/j.ijpharm.2017.07.085 28778627
    [Google Scholar]
  30. Lee M.J. Ye A.S. Gardino A.K. Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell 2012 149 4 780 794 10.1016/j.cell.2012.03.031 22579283
    [Google Scholar]
  31. Goffin J.R. Zbuk K. Epidermal growth factor receptor: pathway, therapies, and pipeline. Clin. Ther. 2013 35 9 1282 1303 10.1016/j.clinthera.2013.08.007 24054705
    [Google Scholar]
  32. Finn R.S. Press M.F. Dering J. Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancer. J. Clin. Oncol. 2009 27 24 3908 3915 10.1200/JCO.2008.18.1925 19620495
    [Google Scholar]
  33. Nielsen T.O. Hsu F.D. Jensen K. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin. Cancer Res. 2004 10 16 5367 5374 10.1158/1078‑0432.CCR‑04‑0220 15328174
    [Google Scholar]
  34. Teng Y.H.F. Tan W.J. Thike A.A. Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy. Breast Cancer Res. 2011 13 2 R35 10.1186/bcr2857 21457545
    [Google Scholar]
  35. Yamashita N. Tokunaga E. Iwasa S. Katsumata N. Fujiwara Y. Hoshina S. Epidermal growth factor receptor gene copy number and protein expression in triple-negative breast cancer: prognostic significance and potential as a therapeutic target. Cancer Sci. 2013 104 11 1341 1347
    [Google Scholar]
  36. Bhattarai S. Bajpai M. Neupane S. Thapa P. Neupane R. EGFR-targeted therapies in triple-negative breast cancer: current status and future perspectives. Cancer Treat. Rev. 2022 103 102331
    [Google Scholar]
  37. Vagia E. Cristofanilli M. New treatment strategies for inflammatory breast cancer. Curr. Treat. Options Oncol. 2021 22 6 50 10.1007/s11864‑021‑00843‑2 33893888
    [Google Scholar]
  38. Mueller K.L. Yang Z.Q. Haddad R. Ethier S.P. Boerner J.L. EGFR/Met association regulates EGFR TKI resistance in breast cancer. J. Mol. Signal. 2010 5 8 10.1186/1750‑2187‑5‑8 20624308
    [Google Scholar]
  39. de Laurentiis M. Mustacchi G. Baglietto L. Amphiregulin neutralization inhibits EGFR signaling and growth of inflammatory breast cancer cells. Breast Cancer Res. Treat. 2013 138 2 427 435 23479422
    [Google Scholar]
  40. Maennling A.E. Tur M.K. Niebert M. Molecular targeting therapy against EGFR family in breast cancer: progress and future potentials. Cancers (Basel) 2019 11 12 1826 10.3390/cancers11121826 31756933
    [Google Scholar]
  41. Kagihara J.A. Andress M. Diamond J.R. Nab-paclitaxel and atezolizumab for the treatment of PD-L1-positive, metastatic triple-negative breast cancer: review and future directions. Expert Rev. Precis. Med. Drug Dev. 2020 5 2 59 65 10.1080/23808993.2020.1730694 32190733
    [Google Scholar]
  42. Shajahan-Haq A.N. Cook K.L. Schwartz-Roberts J.L. MYC regulates the unfolded protein response and glucose and glutamine uptake in endocrine resistant breast cancer. Mol. Cancer 2014 13 1 239 10.1186/1476‑4598‑13‑239 25339305
    [Google Scholar]
  43. McNeil C.M. Sergio C.M. Anderson L.R. c-Myc overexpression and endocrine resistance in breast cancer. J. Steroid Biochem. Mol. Biol. 2006 102 1-5 147 155 10.1016/j.jsbmb.2006.09.028 17052904
    [Google Scholar]
  44. Lassus H. Leminen A. Early growth response protein 1 (EGR1): a friend or foe in cancer? Cell. Mol. Life Sci. 2016 73 23 3831 3845 10.1007/s00018‑016‑2238‑4
    [Google Scholar]
  45. Wei X. Yao L. Jin J. EGR1 regulates breast cancer progression by modulating mitochondrial metabolism. Oncogene 2021 40 14 2590 2604 10.1038/s41388‑021‑01670‑w
    [Google Scholar]
  46. Dubik D. Dembinski T.C. Shiu R.P. Estrogen activates raf-1 kinase and induces expression of Egr-1 in MCF-7 breast cancer cells. Endocrinology 1999 140 11 5199 5206 10.1210/endo.140.11.7136
    [Google Scholar]
  47. Saha S.K. Islam S.M.R. Saha T. Prognostic role of EGR1 in breast cancer: a systematic review. BMB Rep. 2021 54 10 497 504 10.5483/BMBRep.2021.54.10.087 34488929
    [Google Scholar]
  48. Kumbrink J. Gerlinger M. Johnson J.P. Egr-1 induces the expression of its corepressor nab2 by activation of the nab2 promoter thereby establishing a negative feedback loop. J. Biol. Chem. 2005 280 52 42785 42793 10.1074/jbc.M511079200 16260776
    [Google Scholar]
  49. Wei L.L. Zhang X. Wei X. Egr-1 suppresses breast cancer cells proliferation by directly activating p21 expression. Oncol. Lett. 2017 14 5 5645 5652 10.3892/ol.2017.6847
    [Google Scholar]
  50. Wong K.M. Ojo D. Yan J. Tang D. CTCF and EGR1 suppress breast cancer cell migration and invasion by transcriptionally activating Nm23-H1. Sci. Rep. 2021 11 2392 10.1038/s41598‑020‑79869‑9 33436746
    [Google Scholar]
  51. Zhou Y. Yao Z. Lin Y. Zhang H. From tyrosine kinases to tyrosine phosphatases: new therapeutic targets in cancers and beyond. Pharmaceutics 2024 16 7 888 10.3390/pharmaceutics16070888 39065585
    [Google Scholar]
  52. Finn R.S. Dering J. Ginther C. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/“triple-negative” breast cancer cell lines growing in vitro. Breast Cancer Res. Treat. 2007 105 3 319 326 10.1007/s10549‑006‑9463‑x 17268817
    [Google Scholar]
  53. Bartlett J.M.S. Brookes C.L. Robson T. Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the tamoxifen and exemestane adjuvant multinational trial. J. Clin. Oncol. 2011 29 12 1531 1538 10.1200/JCO.2010.30.3677 21422407
    [Google Scholar]
  54. DeSantis C.E. Ma J. Gaudet M.M. Breast cancer statistics, 2019. CA Cancer J. Clin. 2019 69 6 438 451 10.3322/caac.21583 31577379
    [Google Scholar]
  55. Dowsett M. Sestak I. Regan M.M. Integration of clinical variables for the prediction of late distant recurrence in patients with estrogen receptor-positive breast cancer treated with 5 years of endocrine therapy: CTS5. J. Clin. Oncol. 2018 36 19 1941 1948 10.1200/JCO.2017.76.4258 29676944
    [Google Scholar]
  56. Smith A.B. Role of early growth response 1 in endocrine responsiveness and cell proliferation of breast cancer. J. Cancer Res. 2022 14 3 123 136
    [Google Scholar]
  57. Shajahan-Haq A.N. Boca S.M. Jin L. EGR1 regulates cellular metabolism and survival in endocrine resistant breast cancer. Oncotarget 2017 8 57 96865 96884 10.18632/oncotarget.18292 29228577
    [Google Scholar]
  58. Osborne C.K. Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu. Rev. Med. 2011 62 1 233 247 10.1146/annurev‑med‑070909‑182917 20887199
    [Google Scholar]
  59. Cairns J. Ingle J.N. Kalari K.R. The lncRNA MIR2052HG regulates ERα levels and aromatase inhibitor resistance through LMTK3 by recruiting EGR1. Breast Cancer Res. 2019 21 1 47 10.1186/s13058‑019‑1130‑3 30944027
    [Google Scholar]
  60. Wilder P.T. Weber D.J. Winstead A. Unprecedented anticancer activities of organorhenium sulfonato and carboxylato complexes against hormone-dependent MCF-7 and hormone-independent triple-negative MDA-MB-231 breast cancer cells. Mol. Cell. Biochem. 2018 441 1-2 151 163 10.1007/s11010‑017‑3181‑z 28913709
    [Google Scholar]
  61. Yeo S.K. Guan J.L. Breast cancer: multiple subtypes within a tumor? Trends Cancer 2017 3 11 753 760 10.1016/j.trecan.2017.09.001 29120751
    [Google Scholar]
  62. Patel H.K. Bihani T. Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment. Pharmacol. Ther. 2018 186 1 24 10.1016/j.pharmthera.2017.12.012 29289555
    [Google Scholar]
  63. Lu Y. Liu W. Selective estrogen receptor degraders (SERDs): a promising strategy for estrogen receptor positive endocrine-resistant breast cancer. J. Med. Chem. 2020 63 24 15094 15114 10.1021/acs.jmedchem.0c00913 33138369
    [Google Scholar]
  64. Rani A. Stebbing J. Giamas G. Murphy J. Endocrine resistance in hormone receptor positive breast cancer–from mechanism to therapy. Front. Endocrinol. (Lausanne) 2019 10 245 10.3389/fendo.2019.00245 31178825
    [Google Scholar]
  65. Ferreira Almeida C. Oliveira A. João Ramos M. Fernandes P.A. Teixeira N. Amaral C. Estrogen receptor-positive (ER+) breast cancer treatment: Are multi-target compounds the next promising approach? Biochem. Pharmacol. 2020 177 113989 10.1016/j.bcp.2020.113989 32330493
    [Google Scholar]
  66. Farkas S. Szabó A. Hegyi A.E. Estradiol and estrogen-like alternative therapies in use: the importance of the selective and nonclassical actions. Biomedicines 2022 10 4 861 10.3390/biomedicines10040861 35453610
    [Google Scholar]
  67. Cagnet S. Ataca D. Sflomos G. Oestrogen receptor α AF-1 and AF-2 domains have cell population-specific functions in the mammary epithelium. Nat. Commun. 2018 9 1 4723 10.1038/s41467‑018‑07175‑0 30413705
    [Google Scholar]
  68. Hernando C. Ortega-Morillo B. Tapia M. Oral selective estrogen receptor degraders (SERDs) as a novel breast cancer therapy: present and future from a clinical perspective. Int. J. Mol. Sci. 2021 22 15 7812 10.3390/ijms22157812 34360578
    [Google Scholar]
  69. Tecalco-Cruz A.C. Pérez-Alvarado I.A. Ramírez-Jarquín J.O. Rocha-Zavaleta L. Nucleo-cytoplasmic transport of estrogen receptor alpha in breast cancer cells. Cell. Signal. 2017 34 121 132 10.1016/j.cellsig.2017.03.011 28341599
    [Google Scholar]
  70. Kowalczyk W. Waliszczak G. Jach R. Dulińska-Litewka J. Steroid receptors in breast cancer: Understanding of molecular function as a basis for effective therapy development. Cancers (Basel) 2021 13 19 4779 10.3390/cancers13194779 34638264
    [Google Scholar]
  71. Pawlak M. Lefebvre P. Staels B. General molecular biology and architecture of nuclear receptors. Curr. Top. Med. Chem. 2012 12 6 486 504 10.2174/156802612799436641 22242852
    [Google Scholar]
  72. Yu J. Mu Q. Fung M. Xu X. Zhu L. Ho R.J.Y. Challenges and opportunities in metastatic breast cancer treatments: Nano-drug combinations delivered preferentially to metastatic cells may enhance therapeutic response. Pharmacol. Ther. 2022 236 108108 10.1016/j.pharmthera.2022.108108 34999182
    [Google Scholar]
  73. Clusan L. Ferrière F. Flouriot G. Pakdel F. A basic review on estrogen receptor signalling pathways in breast cancer. Int. J. Mol. Sci. 2023 24 7 6834 10.3390/ijms24076834 37047814
    [Google Scholar]
  74. Yuan Y. Long H. Zhou Z. Fu Y. Jiang B. PI3K-AKT-targeting breast cancer treatments: Natural products and synthetic compounds. Biomolecules 2023 13 1 93 10.3390/biom13010093 36671478
    [Google Scholar]
  75. Braicu C. Buse M. Busuioc C. A comprehensive review on MAPK: A promising therapeutic target in cancer. Cancers (Basel) 2019 11 10 1618 10.3390/cancers11101618 31652660
    [Google Scholar]
  76. Acosta-Ramos E. Segovia-Mendoza M. Olivares-Reyes J.A. Growth factor receptor implications in breast cancer: Prospects for their molecular transactivation in the future and obstacles for target therapy. Breast Cancer Treatment: An Interdisciplinary Approach. Rezaei N. Cham Springer 2024 237 301 10.1007/16833_2024_281
    [Google Scholar]
  77. Boz Er A.B. Er I. Targeting ITGβ3 to overcome trastuzumab resistance through epithelial–mesenchymal transition regulation in HER2-positive breast cancer. Int. J. Mol. Sci. 2024 25 16 8640 10.3390/ijms25168640 39201327
    [Google Scholar]
  78. Dhillon A.S. Hagan S. Rath O. Kolch W. MAP kinase signalling pathways in cancer. Oncogene 2007 26 22 3279 3290 10.1038/sj.onc.1210421 17496922
    [Google Scholar]
  79. Mortezaee K. Majidpoor J. Kharazinejad E. Epithelial-mesenchymal transition in cancer stemness and heterogeneity: updated. Med. Oncol. 2022 39 12 193 10.1007/s12032‑022‑01801‑0 36071302
    [Google Scholar]
  80. Peinado H. Olmeda D. Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat. Rev. Cancer 2007 7 6 415 428 10.1038/nrc2131 17508028
    [Google Scholar]
  81. Delozier T. Switsers O. Génot J.Y. Delayed adjuvant tamoxifen: Ten-year results of a collaborative randomized controlled trial in early breast cancer (TAM-02 trial). Ann. Oncol. 2000 11 5 515 520 10.1023/A:1008321415065 10907942
    [Google Scholar]
  82. Deal C.L. Draper M.W. Raloxifene: a selective estrogen-receptor modulator for postmenopausal osteoporosis - a clinical update on efficacy and safety. Womens Health (Lond. Engl.) 2006 2 2 199 210 10.2217/17455057.2.2.199 19803890
    [Google Scholar]
  83. Vogel V.G. Costantino J.P. Wickerham D.L. Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006 295 23 2727 2741 10.1001/jama.295.23.joc60074 16754727
    [Google Scholar]
  84. Bevers T.B. Ward J.H. Arun B.K. Breast cancer risk reduction, version 2.2015. J. Natl. Compr. Canc. Netw. 2015 13 7 880 915 10.6004/jnccn.2015.0105 26150582
    [Google Scholar]
  85. Heldring N. Pawson T. McDonnell D. Treuter E. Gustafsson J.Å. Pike A.C.W. Structural insights into corepressor recognition by antagonist-bound estrogen receptors. J. Biol. Chem. 2007 282 14 10449 10455 10.1074/jbc.M611424200 17283072
    [Google Scholar]
  86. Cummings S.R. McClung M. Reginster J.Y. Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women. J. Bone Miner. Res. 2011 26 2 397 404 10.1002/jbmr.191 20658564
    [Google Scholar]
  87. Pike A.C.W. Brzozowski A.M. Hubbard R.E. Structure of the ligand-binding domain of oestrogen receptor alpha in complex with raloxifene. Nature 2001 410 6826 529 533 10.1038/35069078
    [Google Scholar]
  88. Johnston S.R.D. Kilburn L.S. Ellis P. Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. Lancet Oncol. 2013 14 10 989 998 10.1016/S1470‑2045(13)70322‑X 23902874
    [Google Scholar]
  89. Deshmane V. Krishnamurthy S. Melemed A.S. Peterson P. Buzdar A.U. Phase III double-blind trial of arzoxifene compared with tamoxifen for locally advanced or metastatic breast cancer. J. Clin. Oncol. 2007 25 31 4967 4973 10.1200/JCO.2006.09.5992 17971595
    [Google Scholar]
  90. González-Martínez S. Pérez-Mies B. Pizarro D. Caniego-Casas T. Cortés J. Palacios J. Epithelial mesenchymal transition and immune response in metaplastic breast carcinoma. Int. J. Mol. Sci. 2021 22 14 7398 10.3390/ijms22147398 34299016
    [Google Scholar]
  91. Zaluzec E.K. Sempere L.F. Systemic and local strategies for primary prevention of breast cancer. Cancers (Basel) 2024 16 2 248 10.3390/cancers16020248 38254741
    [Google Scholar]
  92. Yavropoulou M.P. Makras P. Anastasilakis A.D. Bazedoxifene for the treatment of osteoporosis. Expert Opin. Pharmacother. 2019 20 10 1201 1210 10.1080/14656566.2019.1615882 31091133
    [Google Scholar]
  93. Pinkerton J.V. Archer D.F. Utian W.H. Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis. Menopause 2009 16 6 1102 1108 10.1097/gme.0b013e3181a816be 19546825
    [Google Scholar]
  94. Fisher B. Anderson S. Tan-Chiu E. Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. J. Clin. Oncol. 2001 19 4 931 942 10.1200/JCO.2001.19.4.931 11181655
    [Google Scholar]
  95. Wardell S.E. Nelson E.R. Chao C.A. McDonnell D.P. Bazedoxifene exhibits antiestrogenic activity in animal models of tamoxifen-resistant breast cancer: implications for treatment of advanced disease. Clin. Cancer Res. 2013 19 9 2420 2431 10.1158/1078‑0432.CCR‑12‑3771 23536434
    [Google Scholar]
  96. Bhatia N. Hazra S. Thareja S. Selective Estrogen receptor degraders (SERDs) for the treatment of breast cancer: An overview. Eur. J. Med. Chem. 2023 256 115422 10.1016/j.ejmech.2023.115422 37163948
    [Google Scholar]
  97. Demetriou D. Khanyile R. Mbita Z. Dlamini Z. Resistance to endocrine therapy in breast cancer. Overcoming Breast Cancer Therapy Resistance. Cham Springer 2024 105 128 10.1007/978‑3‑031‑52860‑6_5
    [Google Scholar]
  98. Fujii R. Lee B.S. Akiyama Y. Mori S. Tsunoda N. Takeuchi Y. Lasofoxifene and bazedoxifene as estrogen receptor modulators in breast cancer cells: Proliferation and transcriptome analyses. Breast Cancer Res. Treat. 2012 132 2 709 723
    [Google Scholar]
  99. Cummings S.R. Ensrud K. Delmas P.D. Lasofoxifene in postmenopausal women with osteoporosis. N. Engl. J. Med. 2010 362 8 686 696 10.1056/NEJMoa0808692 20181970
    [Google Scholar]
  100. Hajjo R. Sabbah D.A. Bardaweel S.K. Zhong H.A. Targeting the EGFR/RAS/RAF signaling pathway in anticancer research: A recent update on inhibitor design and clinical trials (2020–2023). Expert Opin. Ther. Pat. 2024 34 51
    [Google Scholar]
  101. Zhang J. Liang Q. Lei Y. Yao M. Li L. Gao X. Overexpression of EGFR is an independent prognostic factor for the progression and poor prognosis of triple-negative breast cancer overall and in Asians: a meta-analysis. Oncotarget 2017 8 25 32368 32379
    [Google Scholar]
  102. Pernas S. Tolaney S.M. HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance. Ther. Adv. Med. Oncol. 2019 11 1758835919833519 10.1177/1758835919833519 30911337
    [Google Scholar]
  103. Lehmann B.D. Bauer J.A. Chen X. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Invest. 2011 121 7 2750 2767 10.1172/JCI45014 21633166
    [Google Scholar]
  104. Baselga J. Cortés J. Kim S.B. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N. Engl. J. Med. 2012 366 2 109 119 10.1056/NEJMoa1113216 22149875
    [Google Scholar]
  105. Swain S.M. Baselga J. Kim S.B. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N. Engl. J. Med. 2015 372 8 724 734 10.1056/NEJMoa1413513 25693012
    [Google Scholar]
  106. Sammons S. Shastry M. Dent S. Anders C. Hamilton E. Practical treatment strategies and future directions after progression while receiving CDK4/6 inhibition and endocrine therapy in advanced HR+/HER2− breast cancer. Clin. Breast Cancer 2020 20 1 1 11 10.1016/j.clbc.2019.06.017 31780379
    [Google Scholar]
  107. Jameera Begam A. Jubie S. Nanjan M.J. Estrogen receptor agonists/antagonists in breast cancer therapy: A critical review. Bioorg. Chem. 2017 71 257 274 10.1016/j.bioorg.2017.02.011 28274582
    [Google Scholar]
  108. Roberto M. Astone A. Botticelli A. CDK4/6 inhibitor treatments in patients with hormone receptor-positive, HER2-negative advanced breast cancer: Potential molecular mechanisms, clinical implications and future perspectives. Cancers (Basel) 2021 13 2 332 10.3390/cancers13020332 33477469
    [Google Scholar]
  109. Cescon D.W. Schmid P. Rugo H.S. Health-related quality of life with pembrolizumab plus chemotherapy vs. placebo plus chemotherapy for advanced triple-negative breast cancer: KEYNOTE-355. J. Natl. Cancer Inst. 2024 116 5 717 727 10.1093/jnci/djad240 38070159
    [Google Scholar]
  110. Braal C.L. Jongbloed E.M. Wilting S.M. Mathijssen R.H.J. Koolen S.L.W. Jager A. Inhibiting CDK4/6 in breast cancer with palbociclib, ribociclib, and abemaciclib: similarities and differences. Drugs 2021 81 3 317 331 10.1007/s40265‑020‑01461‑2 33369721
    [Google Scholar]
  111. Schwartzberg L.S. Vidal G.A. Targeting PIK3CA alterations in hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: New therapeutic approaches and practical considerations. Clin. Breast Cancer 2020 20 4 e439 e449 10.1016/j.clbc.2020.02.002 32278641
    [Google Scholar]
  112. Nakai K. Hung M.C. Yamaguchi H. A perspective on anti-EGFR therapies targeting triple-negative breast cancer. Am. J. Cancer Res. 2016 6 8 1609 1623 27648353
    [Google Scholar]
  113. Asati V. Mahapatra D.K. Bharti S.K. PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives. Eur. J. Med. Chem. 2016 109 314 341 10.1016/j.ejmech.2016.01.012 26807863
    [Google Scholar]
  114. Saleh R. Taha R.Z. Sasidharan Nair V. Alajez N.M. Elkord E. PD-L1 blockade by atezolizumab downregulates signalling pathways associated with tumor growth, metastasis, and hypoxia in human triple negative breast cancer. Cancers (Basel) 2019 11 8 1050 10.3390/cancers11081050 31349612
    [Google Scholar]
  115. Bartsch R. ASCO 2023: Highlights in breast cancer. Mag. Eur. Med. Oncol. 2024 17 2 96 99 10.1007/s12254‑023‑00936‑8
    [Google Scholar]
  116. Qiang Z. Wan J. Chen X. Wang H. Mechanisms and therapeutic targets of ErbB family receptors in hepatocellular carcinoma: A narrative review. Transl. Cancer Res. 2024 13 6 3156 3178 10.21037/tcr‑24‑837 38988928
    [Google Scholar]
  117. Untch M. Jackisch C. Schneeweiss A. NAB-paclitaxel improves disease-free survival in early breast cancer: GBG 69-GeparSepto. J. Clin. Oncol. 2019 37 25 2226 2234 10.1200/JCO.18.01842 31082269
    [Google Scholar]
  118. Yoon J. Oh D.Y. HER2-targeted therapies beyond breast cancer — an update. Nat. Rev. Clin. Oncol. 2024 21 9 675 700 10.1038/s41571‑024‑00924‑9 39039196
    [Google Scholar]
  119. Pan L. Li J. Xu Q. HER2/PI3K/AKT pathway in HER2-positive breast cancer: A review. Medicine (Baltimore) 2024 103 24 38508 10.1097/MD.0000000000038508 38875362
    [Google Scholar]
  120. Anitha K. Chenchula S. Surendran V. Advancing cancer theranostics through biomimetics: A comprehensive review. Heliyon 2024 10 6 27692 10.1016/j.heliyon.2024.e27692 38496894
    [Google Scholar]
  121. Mohammadpour Z. Majidzadeh-A K. Applications of two-dimensional nanomaterials in breast cancer theranostics. ACS Biomater. Sci. Eng. 2020 6 4 1852 1873 10.1021/acsbiomaterials.9b01894 33455353
    [Google Scholar]
  122. Jiemy W.F. Heeringa P. Kamps J.A.A.M. van der Laken C.J. Slart R.H.J.A. Brouwer E. Positron emission tomography (PET) and single photon emission computed tomography (SPECT) imaging of macrophages in large vessel vasculitis: Current status and future prospects. Autoimmun. Rev. 2018 17 7 715 726 10.1016/j.autrev.2018.02.006 29729443
    [Google Scholar]
  123. Bénard F. Turcotte É. Imaging in breast cancer: Single-photon computed tomography and positron-emission tomography. Breast Cancer Res. 2005 7 4 153 162 10.1186/bcr1201 15987467
    [Google Scholar]
  124. Buijs S.M. van Dorst D.C.H. Kruip M.J.H.A. The interplay between tamoxifen and endoxifen plasma concentrations and coagulation parameters in patients with primary breast cancer. Biomed. Pharmacother. 2024 170 115969 10.1016/j.biopha.2023.115969 38042112
    [Google Scholar]
  125. Haddad T.C. Suman V.J. Giridhar K.V. Anastrozole dose escalation for optimal estrogen suppression in postmenopausal early-stage breast cancer: A prospective trial. Clin. Cancer Res. 2024 30 15 3147 3156 10.1158/1078‑0432.CCR‑24‑0341 38752717
    [Google Scholar]
  126. Kingston B. Pearson A. Herrera-Abreu M.T. ESR1 F404 mutations and acquired resistance to fulvestrant in ESR1-mutant breast cancer. Cancer Discov. 2024 14 2 274 289 10.1158/2159‑8290.CD‑22‑1387 37982575
    [Google Scholar]
  127. Wilson F.R. Coombes M.E. Wylie Q. Herceptin® (trastuzumab) in HER2-positive early breast cancer: protocol for a systematic review and cumulative network meta-analysis. Syst. Rev. 2017 6 1 196 10.1186/s13643‑017‑0588‑2 29017563
    [Google Scholar]
  128. Kothari R. Doshi M. Chaithanya P.K. A randomized, double-blind, phase III study in India for comparing efficacy, safety, and PK of ZRC-3277 (pertuzumab biosimilar) with Perjeta® in patients with HER2-positive metastatic breast cancer. Clin. Breast Cancer 2024 24 7 639 646.e2 10.1016/j.clbc.2024.07.001 39069436
    [Google Scholar]
  129. Fehm T. Mueller V. Banys-Paluchowski M. Efficacy of lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells—the DETECT III clinical trial. Clin. Chem. 2024 70 1 307 318 10.1093/clinchem/hvad144 38175595
    [Google Scholar]
  130. Serrero G. Yue B. Dong J. Hayashi J. Combination of trastuzumab competing and non-competing fully human internalizing anti-Her2 monoclonal antibody drug conjugates increases their inhibitory effect on the growth of HER2 positive metastatic breast cancer cells. Cancer Res. 2024 84 9 PO5 PO04.(Suppl.) 10.1158/1538‑7445.SABCS23‑PO5‑04‑02
    [Google Scholar]
  131. Cejuela M. Gil-Torralvo A. Castilla M.Á. Abemaciclib, palbociclib, and ribociclib in real-world data: a direct comparison of first-line treatment for endocrine-receptor-positive metastatic breast cancer. Int. J. Mol. Sci. 2023 24 10 8488 10.3390/ijms24108488 37239834
    [Google Scholar]
  132. Moreau-Bachelard C. Robert M. Gourmelon C. Evaluating everolimus for the treatment of breast cancer. Expert Opin. Pharmacother. 2023 24 10 1105 1111 10.1080/14656566.2023.2214677 37183684
    [Google Scholar]
  133. Chenchula S. Atal S. Uppugunduri C.R.S. A review of real-world evidence on preemptive pharmacogenomic testing for preventing adverse drug reactions: a reality for future health care. Pharmacogenomics J. 2024 24 2 9 10.1038/s41397‑024‑00326‑1 38490995
    [Google Scholar]
  134. Anitha K. Posinasetty B. Naveen Kumari K. Liquid biopsy for precision diagnostics and therapeutics. Clin. Chim. Acta 2024 554 117746 10.1016/j.cca.2023.117746 38151071
    [Google Scholar]
  135. Chenchula S. Atal S. Bhattacharyya A. Medhi B. Chavan M. Sarma P. Pharmacomicrobiomics – Another frontier of precision medicine. Indian J. Pharmacol. 2024 56 4 237 241 10.4103/ijp.ijp_646_24 39250619
    [Google Scholar]
  136. Özyurt C. Uludağ İ. İnce B. Sezgintürk M.K. Lab-on-a-chip systems for cancer biomarker diagnosis. J. Pharm. Biomed. Anal. 2024 241 115760 36706542
    [Google Scholar]
  137. Popova A.A. Levkin P.A. Precision medicine in oncology: in vitro drug sensitivity and resistance test (DSRT) for selection of personalized anticancer therapy. Adv. Ther. (Weinh.) 2020 3 2 1900100 10.1002/adtp.201900100
    [Google Scholar]
  138. Ermis M. Antmen E. Kuren O. Demirci U. Hasirci V. A cell culture chip with transparent, micropillar-decorated bottom for live cell imaging and screening of breast cancer cells. Micromachines (Basel) 2022 13 1 93 10.3390/mi13010093 35056257
    [Google Scholar]
  139. Frankman Z.D. Jiang L. Schroeder J.A. Zohar Y. Application of microfluidic systems for breast cancer research. Micromachines (Basel) 2022 13 2 152 10.3390/mi13020152 35208277
    [Google Scholar]
  140. Vikram R. Chou W.C. Hung S.C. Shen C.Y. Tumorigenic and metastatic role of CD44−/low/CD24−/low cells in luminal breast cancer. Cancers (Basel) 2020 12 5 1239 10.3390/cancers12051239 32423137
    [Google Scholar]
  141. Kalot R. Mhanna R. Talhouk R. Organ-on-a-chip platforms as novel advancements for studying heterogeneity, metastasis, and drug efficacy in breast cancer. Pharmacol. Ther. 2022 237 108156 10.1016/j.pharmthera.2022.108156 35150784
    [Google Scholar]
  142. Firatligil-Yildirir B. Yalcin-Ozuysal O. Nonappa. Recent advances in lab-on-a-chip systems for breast cancer metastasis research. Nanoscale Adv. 2023 5 9 2375 2393 10.1039/D2NA00823H 37143816
    [Google Scholar]
  143. Elbaiomy M.A. Akl T. Atwan N. Elsayed A.A. Elzaafarany M. Shamaa S. Clinical impact of breast cancer stem cells in metastatic breast cancer patients. J. Oncol. 2020 2020 1 8 10.1155/2020/2561726 32684928
    [Google Scholar]
  144. Pershina O. Ermakova N. Pakhomova A. Cancer stem cells and somatic stem cells as potential new drug targets, prognosis markers, and therapy efficacy predictors in breast cancer treatment. Biomedicines 2021 9 9 1223 10.3390/biomedicines9091223 34572409
    [Google Scholar]
  145. He L. Wick N. Germans S.K. Peng Y. The role of breast cancer stem cells in chemoresistance and metastasis in triple-negative breast cancer. Cancers (Basel) 2021 13 24 6209 10.3390/cancers13246209 34944829
    [Google Scholar]
  146. Monaco A. Licitra F. Di Gisi M. ERβ in triple-negative breast cancer: emerging concepts and therapeutic possibilities. Endocrines 2021 2 3 356 365 10.3390/endocrines2030033
    [Google Scholar]
  147. Mao X.D. Wei X. Xu T. Li T.P. Liu K.S. Research progress in breast cancer stem cells: characterization and future perspectives. Am. J. Cancer Res. 2022 12 7 3208 3222 35968346
    [Google Scholar]
  148. Li K. Shu D. Li H. SMAD4 depletion contributes to endocrine resistance by integrating ER and ERBB signaling in HR + HER2− breast cancer. Cell Death Dis. 2024 15 6 444 10.1038/s41419‑024‑06838‑9 38914552
    [Google Scholar]
  149. Kishino E. Ogata R. Saitoh W. Anti-cell growth and anti-cancer stem cell activity of the CDK4/6 inhibitor palbociclib in breast cancer cells. Breast Cancer 2020 27 3 415 425 10.1007/s12282‑019‑01035‑5 31823286
    [Google Scholar]
  150. Subhan M.A. Torchilin V.P. Advances in targeted therapy of breast cancer with antibody‒drug conjugate. Pharmaceutics 2023 15 4 1242 10.3390/pharmaceutics15041242 37111727
    [Google Scholar]
  151. Sincere N.I. Anand K. Ashique S. Yang J. You C. PROTACs: emerging targeted protein degradation approaches for advanced druggable strategies. Molecules 2023 28 10 4014 10.3390/molecules28104014 37241755
    [Google Scholar]
  152. Noblejas-López M.M. Tébar-García D. López-Rosa R. TACkling cancer by targeting selective protein degradation. Pharmaceutics 2023 15 10 2442 10.3390/pharmaceutics15102442 37896202
    [Google Scholar]
  153. Bhatt S. Anitha K. Chellappan D.K. Targeting inflammatory signaling in obsessive compulsive disorder: a promising approach. Metab. Brain Dis. 2023 39 2 335 346 10.1007/s11011‑023‑01314‑3 37950815
    [Google Scholar]
  154. Liu R. Liu Z. Chen M. Xing H. Zhang P. Zhang J. Cooperatively designed aptamer-PROTACs for spatioselective degradation of nucleocytoplasmic shuttling protein for enhanced combinational therapy. Chem. Sci. 2023 15 1 134 145 10.1039/D3SC04249A 38131089
    [Google Scholar]
  155. Wang Z. Che S. Yu Z. PROTAC: Novel degradable approach for different targets to treat breast cancer. Eur. J. Pharm. Sci. 2024 198 106793 10.1016/j.ejps.2024.106793 38740076
    [Google Scholar]
/content/journals/cpd/10.2174/0113816128406867251204172244
Loading
Breast Cancer Drug Resistance: Precision Targeting of ER and HER2 Signalling Networks
Bentham Science Publishers ; https://doi.org/10.2174/0113816128406867251204172244
/content/journals/cpd/10.2174/0113816128406867251204172244
/content/journals/cpd/10.2174/0113816128406867251204172244
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: bioinformatics tools ; estrogen receptor ; combination therapies ; drug resistance ; human epidermal growth factor receptor 2 ; Breast cancer

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test